Melinda L. Telli, M.D.
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Oncology
Key Documents
Contact Information
-
Clinical Offices
Stanford Women�s Cancer Center 900 Blake Wilbur Stanford, CA 94305 Tel Work (650) 498-6004 Fax (650) 490-7237
- Academic Offices
Alternate Contact Kari Sreenivasan Email Tel Work 650-725-8738Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Breast Cancer
- Breast Cancer - Medical Oncology
- Triple-negative breast cancer
- Locally advanced breast cancer
- Medical Oncology
Administrative Appointments
- Scientific Program Committee, Triple Negative Breast Cancer/Cytotoxics/Local Therapy, American Society of Clinical Oncology (2010 - 2013)
- Program Committee, ASCO Breast Cancer Symposium (2010 - 2013)
Honors and Awards
- Career Catalyst Research Award, Susan G. Komen for the Cure (2012)
- New Investigator Award, Stanford Cancer Institute (2011)
- Oncology Division Teaching Award, Stanford University School of Medicine (2010, 2012)
- Young Investigator Award, American Society of Clinical Oncology (2009)
- Fellowship Award, Susan G. Komen for the Cure (2008)
- Merit Award, American Society of Clinical Oncology (2008)
Professional Education
| Fellowship: | Stanford Hospital and Clinics CA (2008) |
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2008) |
| B.A.: | University of Pennsylvania, Biology, with Distinction (1996) |
| M.D.: | George Washington University, Medicine, with Distinction (2002) |
| Residency: | Stanford University, Internal Medicine (2005) |
| Fellowship: | Stanford University, Medical Oncology (2008) |
Community and International Work
- Triple Step Toward the Cure, Mill Valley, CA
- Facing Our Risk of Cancer Empowered (FORCE), Tampa, Florida
- Breast Cancer Connections, Palo Alto, CA
Internet Links
Scientific Focus
Current Research Interests
My research focuses on breast cancer treatment and survivorship. My primary research interest is the development of novel strategies for the treatment of early stage triple-negative and BRCA1/2 mutation-associated breast cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
Clinical Trials
- Not Recruiting A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
- Recruiting A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
- Recruiting 18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
- Recruiting Magnetic Resonance Imaging of Breast Cancer
- Recruiting Vitamin D and Breast Cancer: Does Weight Make a Difference?
Publications
- Underestimating cardiac toxicity in cancer trials: lessons learned? J Clin Oncol. 2012; (16): 1916-8
- Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. 2011; (2): 471-8
- PARP inhibitors in cancer: moving beyond BRCA. Lancet Oncol. 2011; (9): 827-8
- Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010; (20): 1644-50
- Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008; (9): 1613-8
- Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007; (23): 3525-33
Help